TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile
Advanced Science · 2025
DOI: 10.1002/advs.202513243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Fei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Receptors, Thyrotropin, Immunotherapy, Adoptive, Thyrotropin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Research Program of Technological Innovation and Application Demonstration, Key Technology Program for Cell Therapy of NCTIB.
Abstract (Originalsprache)
CAR‐T therapy faces significant challenges in solid tumors, including the shortage of targetable antigen and the immunogenicity of CAR molecules. Here, TSHR is identified as specifically expressed in DTC, but absent in other normal tissues, making it an ideal target for CAR‐T therapy. To overcome CAR immunogenicity, a novel CAR molecule is engineered using TSH (TSH‐CAR), the natural ligand of TSHR, as the antigen‐binding domain to target TSHR. The TSH‐CAR‐T cells demonstrate effective antitumor activity against TSHR‐positive differentiated thyroid cancer (DTC) cell lines in vitro, accompanied by cytokine release (IFNγ, IL‐2) and robust proliferation. In addition, TSH‐CAR‐T cells achieved complete tumor eradication and sustained remission in two distinct thyroid cancer xenograft models. Furthermore, for comprehensively evaluate the safety profile of TSH‐CAR‐T cell, a murine TSH‐CAR (mTSH‐CAR‐T) is engineered, revealing that mTSH‐CAR‐T cells effectively control mTSHR‐positive tumor growth without evident on‐target/off‐tumor effect in immunocompetent syngeneic mouse tumor models, except for the transient and reversible impairment of thyroid follicles, which is acceptable given prior thyroidectomy in DTC patients. The potent preclinical efficacy and favorable safety profile strongly support the clinical translation of TSH‐CAR‐T for patients suffering from metastatic and radioiodine‐resistant DTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China.
- Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangsu, 221002, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China.
- Department of General Surgery, the Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, 221002, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, Jiangsu, 221002, China.
- Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
ORCID-Profile: Fei Wang, Junnian Zheng, Chuan Xu, Hongwei Du
Förderung
- National Natural Science Foundation of China
- Chongqing Research Program of Technological Innovation and Application Demonstration
- Key Technology Program for Cell Therapy of NCTIB
- Social Development Key Project of Jiangsu Province
- Natural Science Foundation Key Project of the Jiangsu Higher Education Department
- Specially Appointed Medical Expert Program of Jiangsu Province of China, Health Innovation Team of Jiangsu Province of China
- Youth Science and Technology Innovation Team Training Program of Xuzhou Medical University
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
Zitieren
APA
Wang, F., Zuo, H., Liu, L., Wang, S., Zhao, H., Liu, Z., Wang, G., Liu, Z., Zheng, J., Xu, C., & Du, H. (2025). TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile. Advanced Science. https://doi.org/10.1002/advs.202513243
Vancouver
Wang F, Zuo H, Liu L, Wang S, Zhao H, Liu Z, et al. TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile. Advanced Science. 2025. doi:10.1002/advs.202513243
BibTeX
@article{Wang2025,
author = {Wang, Fei and Zuo, Hui and Liu, Li and Wang, Shiyuan and Zhao, Haifang and Liu, Zhao and Wang, Gang and Liu, Zhao and Zheng, Junnian and Xu, Chuan and Du, Hongwei},
title = {TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202513243}
}
EUVIMED